About MaxCyte
MaxCyte is a company based in Gaithersburg (United States) founded in 1998.. MaxCyte has raised $20.69 million across 14 funding rounds from investors including HHS, Harbert Management and Casdin Capital. The company has 114 employees as of December 31, 2024. MaxCyte has completed 1 acquisition, including SeQure Dx. MaxCyte offers products and services including Electroporation Systems, Processing Assemblies, and Reagents. MaxCyte operates in a competitive market with competitors including SQZBiotech, Gemini Bio, Fluxion Biosciences, Berkeley Lights and LBT Innovations, among others.
- Headquarter Gaithersburg, United States
- Employees 114 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Maxcyte, Inc.
-
Annual Revenue
$38.63 M-6.44as on Dec 31, 2024
-
Net Profit
$-41.05 M-8.26as on Dec 31, 2024
-
EBITDA
$-46.74 M-6.13as on Dec 31, 2024
-
Total Equity Funding
$20.69 M (USD)
in 14 rounds
-
Latest Funding Round
$31.42 M (USD), Post-IPO
May 01, 2020
-
Investors
HHS
& 6 more
-
Employee Count
114
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MaxCyte
MaxCyte is a publicly listed company on the NASDAQ with ticker symbol MXCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MaxCyte
MaxCyte offers a comprehensive portfolio of products and services, including Electroporation Systems, Processing Assemblies, and Reagents. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Devices for efficient cell transfection in therapy and research
Components for scalable electroporation workflows
Buffers and accessories for cell engineering processes
Unlock access to complete
Unlock access to complete
Funding Insights of MaxCyte
MaxCyte has successfully raised a total of $20.69M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.42 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Post-IPO — $31.4M
-
First Round
First Round
(24 Mar 2004)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Post-IPO - MaxCyte | Valuation |
investors |
|
| Feb, 2019 | Amount | Post-IPO - MaxCyte | Valuation |
investors |
|
| Sep, 2016 | Amount | Post-IPO - MaxCyte | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MaxCyte
MaxCyte has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Harbert Management and Casdin Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
Stem cell research startups in healthcare are funded and accelerated.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MaxCyte
MaxCyte has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SeQure Dx. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of personalized diagnostics for gene-editing therapies
|
2020 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - MaxCyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Maxcyte Comparisons
Competitors of MaxCyte
MaxCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SQZBiotech, Gemini Bio, Fluxion Biosciences, Berkeley Lights and LBT Innovations, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell therapies are developed using proprietary Cell Squeeze technology.
|
|
| domain | founded_year | HQ Location |
Supplement reagents for cell and gene therapy are manufactured.
|
|
| domain | founded_year | HQ Location |
Microfluidics-based tools for cellular analysis are provided.
|
|
| domain | founded_year | HQ Location |
Microfluidics-based systems for single-cell isolation and analysis are developed.
|
|
| domain | founded_year | HQ Location |
Developer of AI-based automated solutions for the preparation and analysis of microbiology culture specimens
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Maxcyte
Frequently Asked Questions about MaxCyte
When was MaxCyte founded?
MaxCyte was founded in 1998 and raised its 1st funding round 6 years after it was founded.
Where is MaxCyte located?
MaxCyte is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Is MaxCyte a funded company?
MaxCyte is a funded company, having raised a total of $20.69M across 14 funding rounds to date. The company's 1st funding round was a Post-IPO of $760.31K, raised on Mar 24, 2004.
How many employees does MaxCyte have?
As of Dec 31, 2024, the latest employee count at MaxCyte is 114.
What is the annual revenue of MaxCyte?
Annual revenue of MaxCyte is $38.63M as on Dec 31, 2024.
What does MaxCyte do?
MaxCyte was founded in 1998 and is headquartered in Gaithersburg, United States. Operations focus on the biotechnology sector, where instrument systems for cell processing and modification are developed and supplied. Key products include the MaxCyte STX, a flow electroporation-based system for single transfections, and the MaxCyte VLX for large-volume transient transfections. Additional services encompass transfection insourcing, such as producing cells with targets of interest and recombinant proteins.
Who are the top competitors of MaxCyte?
MaxCyte's top competitors include SQZBiotech, Mytos and Thrive Bioscience.
What products or services does MaxCyte offer?
MaxCyte offers Electroporation Systems, Processing Assemblies, and Reagents.
Is MaxCyte publicly traded?
Yes, MaxCyte is publicly traded on NASDAQ under the ticker symbol MXCT.
How many acquisitions has MaxCyte made?
MaxCyte has made 1 acquisition, including SeQure Dx.
Who are MaxCyte's investors?
MaxCyte has 7 investors. Key investors include HHS, Harbert Management, Casdin Capital, Sofinnova Partners, and Maryland Stem Cell Research Fund.
What is MaxCyte's ticker symbol?
The ticker symbol of MaxCyte is MXCT on NASDAQ.